![N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]L-Glutamicacid structure, CAS 137281-23-3](/structures/100000/90884_2_137281_23_3.png)
CAS Number137281-23-3
Synonymsn-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]l-glutamic acid; Pemetrexed; N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid; Alimta; LYA; MFCD00902635; N-{4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid; Pemetrexed acid; N-{4-[2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid
Molecular FormulaC20H21N5O6
Molecular Weight427.42
Density1.6±0.1 g/cm3
AppearanceSolid;White to Blue powder to crystal
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 137281-23-3 |
| Catalog No. | 2A-9090884 |
| Chinese Name | 培美曲塞二钠盐 |
| Synonyms | n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]l-glutamic acid; Pemetrexed; N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid; Alimta; LYA; MFCD00902635; N-{4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid; Pemetrexed acid; N-{4-[2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid |
| Molecular Formula | C20H21N5O6 |
| Molecular Weight | 427.42 |
| Density | 1.6±0.1 g/cm3 |
| Appearance | Solid;White to Blue powder to crystal |
| Water Solubility | Slightly soluble: methanol |
| Storage Condition | 0-10°C; avoid heating |
| Application | Pemetrexed is a folate antagonist (antifolate). Inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide nucleotide formyltransferase (GARFT) with Ki of 1.3 nM, 7.2 nM and 65 |
| HTC | 2933990090 |
| PubChem ID | 525786 |
| SMILES | Nc1nc2[nH]cc(CCc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1 |
| InChI | InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1 |
| InChI Key | WBXPDJSOTKVWSJ-ZDUSSCGKSA-N |
| Bioactivity | Pemetrexed is a novel antifolate, the Ki values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), respectively. Related Catalog Signaling Pathways >> Cell Cycle/DNA Damage >> Antifolate Signaling Pathways >> Autophagy >> Autophagy Natural Products >> Alkaloid Research Areas >> Cancer Target Ki: 1.3 nM (TS), 7.2 nM (DHFR), 65 nM (GARFT)[1] In Vitro Pemetrexed (LY231514) disodium is a novel classical antifolate, the antitumor activity of which may result from simultaneous and multipie inhibition of several key folate-requiring enzymes via its polyglutamated metabolites. Pemetrexed (LY231514) is one of the best substrates that is known for the enzyme FPGS (Km=1.6 μM and Vmax/Km=621). It is likely that polyglutamation and the polyglutamated metabolites of LY231514 play profound roles in determining both the selectivity and the antitumor activity of this novel agent. Whereas LY23l5l4 only moderately inhibits TS (Ki=340 nM, recombinant mouse), the pentaglutamate of LY23l5l4 is 100-fold more potent (Ki=3.4 nM), making LY231514 one of the most potent folate-based TS inhibitors[1]. In Vivo The group of mice treated with PC61 plus Pemetrexed demonstrates statistically longer survival than other groups. In a survival analysis, significantly better survival is observed in the group of mice treated with PC61 plus Pemetrexed compare with those treated with PC61 alone, rat IgG plus Pemetrexed, or no treatment[2]. Kinase Assay AICARFT inhibition assays are carried out at room temperature by monitoring the formation of [6S]-5,6,7,8-tetrahydrofolate from 10-formyl-[6R,S]-5,6,7,8-tetrahydrofolate at A298. All solutions are purged with N2 gas prior to use. The reaction solution contains 33 mM Tris-Cl, pH 7.4, 25 mM KCl, 5 mM 2-Mercaptoethanol, 0.05 mM AICA ribonucleotide, and 16 nM (2 milliunits/mL) of AICARFT. 10-Formyl-[6R,S]-5,6,7,8-tetrahydrofolate concentrations of 0.037, 0.074, and 0.145 mM are used (0.61, 1.23, and 2.45 times its Km value, respectively). LY231514 is tested as an inhibitor at 0.08-0.8 mM (four concentrations). When the tri- and pentaglutamates of LY231514 are used as inhibitors, the concentrations are 0.0005-0.009 mM (eight concentrations). Enzyme assays are initiated by the addition of enzyme. Data is analyzed using the ENZFITTER program for competitive inhibition. Cell Assay Dose-response curves are generated to determine the concentration required for 50% inhibition of growth (IC50). Pemetrexed is dissolved initially in DMSO at a concentration of 4 mg/mL and further diluted with cell culture medium to the desired concentration. CCRF-CEM leukemia cells in complete medium are added to 24-well Cluster plates at a final concentration of 4.8×104 cells/well in a total volume of 2 mL. Test compounds at various concentrations are added to duplicate wells so that the final volume of DMSO is 0.5%. The plates are incubated for 72 h at 37°C in an atmosphere of 5% CO2 in air. At the end of the incubation, cell numbers are determined on a ZBI Coulter counter. Control wells usually contain 4×105 to 6×105 cells at the end of the incubation. For several studies, IC50s are determined for each compound in the presence of either 300 μM AICA, 5 μM thymidine, 100 μM hypoxanthine, or combination of 5 μM hymidine plus 100 μM hypoxanthine[1]. Animal Admin Mice[2] Female CBA mice and female NOD/SCID mice (NOD.CB17-Prkdcscid) at 6-8 wk of age are used. Premetrexed (100 mg/kg) is given i.p. from days 4-8 (5 consecutive d) to tumor-bearing mice to explore the synergistic effect when combined with anti-CD25 Ab or IgG control. The dose and schedule used for Pemetrexed in the current study is determined based on previous studies in mice. References [1]. Shih C, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-23. [2]. Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignantmesothelioma. J Immunol. 2010 Jul 15;185(2):956-66. Chemical & Physical Properties Density 1.6±0.1 g/cm3 Molecular Formula C20H21N5O6 Molecular Weight 427.411 Exact Mass 427.149170 PSA 191.26000 LogP -0.03 Index of Refraction 1.724 InChIKey WBXPDJSOTKVWSJ-ZDUSSCGKSA-N SMILES Nc1nc2[nH]cc(CCc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1 |
| Use of | Pemetrexed is a novel antifolate, the Ki values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), respectively. Properties Name pemetrexed Synonym More Synonyms Pemetrexed disodium Biological Activity Description Pemetrexed is a novel antifolate, the Ki values of the pentaglutamate of LY231514 are 1.3, 7.2, and 65 nM for inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), respectively. Related Catalog Signaling Pathways >> Cell Cycle/DNA Damage >> Antifolate Signaling Pathways >> Autophagy >> Autophagy Natural Products >> Alkaloid Research Areas >> Cancer Ki: 1.3 nM (TS), 7.2 nM (DHFR), 65 nM (GARFT)[1] In Vivo The group of mice treated with PC61 plus Pemetrexed demonstrates statistically longer survival than other groups. In a survival analysis, significantly better survival is observed in the group of mice treated with PC61 plus Pemetrexed compare with those treated with PC61 alone, rat IgG plus Pemetrexed, or no treatment[2]. References [1]. Shih C, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-23. [2]. Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignantmesothelioma. J Immunol. 2010 Jul 15;185(2):956-66. Chemical & Physical Properties Molecular Formula C20H21N5O6 Exact Mass 427.149170 PSA 191.26000 LogP -0.03 Index of Refraction 1.724 InChIKey WBXPDJSOTKVWSJ-ZDUSSCGKSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in Heterocyclic Building Blocks | ||
|---|---|---|
| 6-CHLORO-N-ETHYL-3-PYRIDINEMETHANAMINE | 120739-77-7 | 2A-9090876 |
| 2-(4-Nitrophenyl)-3-piperazin-1-ylmethyl-benzo-[d]imidazo[2,1-b]thiazole | 727975-69-1 | 2A-9090877 |
| 2-(3-Nitrophenyl)-3-piperazin-1-ylmethylimidazo-[1,2-a]pyridine | 727975-37-3 | 2A-9090879 |
| N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]L-glutamicacid,1,5-diethylester,4-methylbenzenesulfonate(1:1) | 165049-28-5 | 2A-9090880 |
| 2-(4-Nitrophenyl)-3-piperazin-1-ylmethyl-imidazo-[1,2-a]pyridine | 728864-97-9 | 2A-9090882 |
| 6-(3-Nitrophenyl)-5-piperazin-1-ylmethyl-imidazo-[2,1-b]thiazole | 727975-62-4 | 2A-9090886 |
| 6-(4-Nitrophenyl)-5-piperazin-1-ylmethyl-imidazo-[2,1-b]thiazole | 727975-61-3 | 2A-9090887 |
| 4-MORPHOLINECARBONITRILE | 1530-89-8 | 2A-9090894 |
| 1-[2-Bromo-4-(methylsulfonyl)phenyl]piperazine | 849035-69-4 | 2A-9090901 |
| cis-Octahydro-isoindoleHcl | 161829-92-1 | 2A-9090902 |
| Browse all Heterocyclic Building Blocks products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS